RA Capital Management NUVL Position
Exited10-Fund ConvergenceRA Capital Management exited their position in Nuvalent Inc. (NUVL) in Q4 2024, after holding the stock for 3 quarters.
The position was first reported in Q2 2024 and has been tracked across 3 quarterly 13F filings.
NUVL is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Neladalkib (NVL-655) in 626 days (Dec 31, 2027), making the timing of RA Capital's position particularly relevant.
Short interest stands at 15.2% of float with 10.9 days to cover, indicating significant bearish positioning against the stock.
About Nuvalent Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
15.2%
10.9 days to cover
RA Capital Management NUVL Position History
Frequently Asked Questions
Does RA Capital Management own NUVL?
No. RA Capital Management exited their position in Nuvalent Inc. (NUVL) in Q4 2024. They previously held the stock for 3 quarters.
How many hedge funds own NUVL?
10 specialist biotech hedge funds currently hold NUVL, including Deerfield Management, Perceptive Advisors, Commodore Capital and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy NUVL?
RA Capital Management's position in NUVL was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's NUVL position increasing or decreasing?
RA Capital Management completely exited their NUVL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NUVLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →